Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

被引：1
|
作者：
Eng, C.
Bendell, J. C.
Bessudo, A.
Gabrail, N. Y.
Diamond, J.
Pande, A. U.
Gorbatchevsky, I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Pacific Oncol Hematol Associates, Encinitas, CA USA
[4] Gabrail Canc Ctr, Canton, OH USA
[5] Daiichi Sankyo, Edison, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527
引用
收藏
页数：1
相关论文
共 26 条
  • [1] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.
    Eng, Cathy
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir Ivanovich
    Langdon, Robert M.
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    Von Roemeling, Reinhard
    Schwartz, Brian E.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
    Eng, Cathy
    Bessudo, Alberto
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir
    Langdon, Robert
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    von Roemeling, Reinhard
    Schwartz, Brian
    Bendell, Johanna C.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 177 - 186
  • [4] Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)
    Lorenza, Rimassa
    Silvia, Bozzarelli
    Stefano, Cordio
    Filippo, Pietrantonio
    Laura, Toppo
    Sara, Lonardi
    Alberto, Zaniboni
    Roberto, Bordonaro
    Maria, Di Bartolomeo
    Wanda, Liguigli
    Vittorina, Zagonel
    Chiara, Tronconi Maria
    Luca, Di Tommaso
    Laura, Giordano
    Armando, Santoro
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G
    Sugimoto, Naotoshi
    Sakai, Daisuke
    Tamura, Takao
    Hara, Hiroki
    Nishina, Tomohiro
    Esaki, Taito
    Okuda, Hiroyuki
    Denda, Tadamichi
    Tsuda, Masahiro
    Satoh, Taroh
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Kuramochi, Hidekazu
    Hosokawa, Ayumu
    Tsuda, Takashi
    Taniguchi, Hiroya
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G
    Sakai, Daisuke
    Taniguchi, Hiroya
    Tamura, Takao
    Sugimoto, Naotoshi
    Esaki, Taito
    Okuda, Hiroyuki
    Matsumoto, Toshihiko
    Yamazaki, Kentaro
    Denda, Tadamichi
    Yamaguchi, Kensei
    Tsuda, Takashi
    Hosokawa, Ayumu
    Makiyama, Akilaka
    Toblmatsu, Kazutoshi
    Goda, Fuminori
    Otsu, Satoshi
    Kishimoto, Junil
    Boku, Narikazu
    Nakamura, Shinichiro
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A phase II trial of high-dose cetuximab (cmab) plus irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (MCRC) who progressed on standard-dose cmab plus irinotecan
    Patta, A. M.
    McMahon, J. A.
    Samborski, C.
    Fakih, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [10] Phase I/II study of 24-hour infusion of irinotecan (CPT-11) in combination with sequential oral leucovorin (LV) and uracil/tegafur (UFT) for patients (PTS) with metastatic colorectal cancer (MCRC)
    Sadahiro, Sotaro
    Maeda, Yuji
    Suzuki, Toshiyuki
    Makuuchi, Hiroyasu
    Kamijo, Akemi
    Murayama, Chieko
    ANNALS OF ONCOLOGY, 2006, 17 : 117 - 117
123